MedTrace Logo

Ketamine for Multiple Sclerosis Fatigue

NCT05378100 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-03-20

No results posted yet for this study

Summary

The proposed study is a single-center, phase II, randomized, double-blind, parallel-group, active-placebo-controlled trial of intravenous low-dose ketamine in patients with MS fatigue.

Conditions

  • Multiple Sclerosis Fatigue

Interventions

DRUG

Ketamine

Infusion of ketamine 0.5 mg/kg over 40 minutes

DRUG

Midazolam

Infusion of midazolam 0.05 mg/kg over 40 minutes

Sponsors & Collaborators

Principal Investigators

  • Bardia Nourbakhsh, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2026-06-01
Completion
2026-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05378100 on ClinicalTrials.gov